Physician profile
Harry L Shufflebarger
NPI 1053369918
$3,488,056.48
in general payments reported to CMS, 2019-2025
15 companies · $468K in 2025
The $468K reported for 2025 was more than what 99% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264K · 2020: $330K · 2021: $476K · 2022: $965K · 2023: $500K · 2024: $485K · 2025: $468K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.4M · Acquisitions: $39K · Consulting Fee: $11K · Travel and Lodging: $925 · Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,400,889.34 |
| Acquisitions | $39,162.43 |
| Consulting Fee | $10,500.00 |
| Travel and Lodging | $925.07 |
| Food and Beverage | $369.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,583,509.56 | 2019-2025 | Everest Spinal System, Direct Inject, Duramatrix |
| Depuy Synthes Products, INC. | $549,100.46 | 2022-2023 | Fibulink |
| Vb Spine LLC | $335,288.97 | 2025 | Yukon Oct Spinal System |
| Integrity Implants INC. | $9,925.68 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $4,673.68 | 2020-2023 | Exparel |
| Seaspine Orthopedics Corporation | $3,959.56 | 2022 | |
| Depuy Synthes Sales INC. | $711.94 | 2019-2022 | |
| Nuvasive, INC. | $404.37 | 2019-2020 | |
| Medtronic, INC. | $313.28 | 2021-2022 | |
| Globus Medical, INC. | $70.43 | 2023 | Creo 5.5 |
| Carlsmed, INC. | $52.17 | 2021-2022 | |
| Urgo Medical North America, LLC | $18.04 | 2023 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Bioventus LLC | $16.11 | 2020 | |
| Kci USA, INC. | $12.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$600,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Shufflebarger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.